New York, January 31, 2026, 10:29 EST — The market has closed.
- JNJ closed almost unchanged Friday, with investors digesting updates on litigation and drug development.
- Attention now turns to regulatory developments in Europe and upcoming moves in U.S. talc litigation.
- Monday’s session offers the first solid insight into whether either thread shifts positioning.
Johnson & Johnson shares edged down 3 cents to $227.25 on Friday after a U.S. judge dismissed a lawsuit accusing the company of fraud related to its talc bankruptcy approach. The plaintiffs claimed J&J employed a “Texas two-step,” moving talc liabilities into a subsidiary that filed for bankruptcy to stall cancer lawsuits. Judge Michael Shipp ruled they hadn’t proven any real harm caused by the delay. J&J’s litigation head Erik Haas slammed the claims as “wholly meritless,” while the plaintiffs’ attorney said they’re considering an appeal. Reuters
U.S. markets are closed for the weekend, leaving traders to weigh how much talc-related risk remains baked in ahead of Monday. The figures tend to stay steady from quarter to quarter, but shifts often hinge on the court docket.
The timing is crucial as J&J juggles two priorities: reducing legal uncertainty and maintaining a rapid pace of new drug launches to drive growth. Slip-ups on either front usually reflect in how investors view the stock’s reputation for steadiness.
On Friday, the European Medicines Agency’s drug committee, the CHMP, recommended expanding the use of Johnson & Johnson’s AKEEGA tablet in Europe. The approval targets patients with metastatic hormone-sensitive prostate cancer who carry BRCA1/2 mutations and are receiving hormone-blocking therapy, known as androgen deprivation therapy. J&J reported that its Phase 3 AMPLITUDE trial showed patients with BRCA mutations experienced longer radiographic progression-free survival, with the median not reached compared to 26 months for those on standard treatment. “Pending approval, the niraparib and abiraterone acetate dual action tablet will offer a targeted treatment strategy,” said oncology executive Henar Hevia. JNJ.com
CHMP opinions are forwarded to the European Commission, which typically issues a legally binding decision within 67 days, according to the EMA. That sets a tentative timeline for the next milestone, although pricing and market adoption could lag behind.
Friday’s subdued action implies investors view the prostate-cancer update as a steady, incremental boost—not a catalyst for immediate gains. Litigation remains the main risk, with markets typically jolting more sharply when that story breaks.
Earlier this month, the company projected 2026 earnings between $11.43 and $11.63 per share, with sales ranging from $99.5 billion to $100.5 billion—exceeding Wall Street’s expectations even after accounting for a U.S. drug-pricing agreement. Chief Executive Joaquin Duato told analysts, “We are confident growth in 2026 will be faster than in 2025.” Reuters
Investors will be closely tracking any updates on the appeal of the dismissed fraud suit in the coming week, along with moves that could influence the broader talc litigation timeline. On the product front, attention turns to how swiftly Europe moves from the CHMP opinion to a formal labeling decision.
Neither path is without risks. Talc-related lawsuits continue to yield hefty verdicts or force costly settlements, while regulators may delay approval by raising concerns about safety, dosing, or patient eligibility.
Johnson & Johnson’s shares face their initial challenge when markets reopen Monday, Feb. 2. Investors will be watching closely to see if they view the talc ruling as genuine risk relief or simply background noise ahead of the next court filing. Following that, attention will shift to the European Commission’s ruling on AKEEGA.
